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We previously found that gender inﬂuenced the JAK2 V617F allele burden, but it is unknown whether this gender diﬀerence in
molecular epidemiology inﬂuences complications in the myeloproliferative neoplasms (MPNs). Historically, vascular complica-
tions represented the most common cause of mortality in polycythemia vera and essential thrombocytosis and contributed to
morbidity in primary myeloﬁbrosis. To determine the inﬂuence of gender on vascular complications, we retrospectively analyzed
associationsbetweengenderandvascularcomplications.Despitetheiryoungerage,lessprevalentdyslipidemiaorsmokinghistory,
lower white blood counts, and lower JAK2 V617F allele burden, women had higher rates of abdominal venous thrombosis and
comparable rates of all vascular complications. Vascular risk is currently not easily stratiﬁed by MPN-disease burden or traditional
risk factors. Our analysis contributes to growing literature emphasizing gender diﬀerences in the MPN and further supports the
important impact of individual and host variation on MPN clinical manifestations, and especially vascular risk.
1.Introduction
Themyeloproliferative neoplasms(MPNs), essentialthrom-
bocytosis(ET),polycythemiavera(PV),andprimarymyelo-
ﬁbrosis (PMF) share the same acquired genetic lesion,
JAK2 V617F, which may explain shared tendencies towards
cardinal complications, which include thrombosis, extra-
medullary hematopoiesis evolution between phenotypes,
and leukemic transformation. However, clinical and patho-
logicdiﬀerencesamongthethreedisordersraisethequestion
as to how a shared genetic lesion could result in three
distinct phenotypes. This question led us to explore the role
of the unique host as a modiﬁer of disease pathogenesis.
We had previously observed gender diﬀerences in disease
distribution, including an overrepresentation of women
among those with ET and PV, and an underrepresentation
of women among those with PMF [1]; also, we found
that similar to historical data [2], PV was manifest at a
younger age in women compared to men in our cohort.
Therefore, we identiﬁed gender as a potential host modiﬁer
of disease pathogenesis and evaluated whether there were
also diﬀerences in the JAK2 V617F allele burden between
men and women. We found that gender inﬂuenced the
JAK2 V617F allele burden within the disease phenotypes and
the magnitude of change in the JAK2 V617F allele burden
through the course of the disease duration, with women
having lower mutational burdens than men [3].
Itisunknownwhetherthesegenderdiﬀerencesinmolec-
ular epidemiology inﬂuence cardinal complications in the
MPN. In our prior analysis, among those that experienced
phenotypic evolution, women were more likely to evolve
from ET to PV, but less likely to evolve from ET to MF [3].
Historical diﬀerences in the experience of extramedullary
hematopoiesis have been reported. For example, it has been
suggested that splenomegaly more commonly complicated
the course in women with PV, but survival was better com-
pared to men [2]. Historical literature has also suggested that
women with myeloﬁbrosis have a longer duration of illness
leading up to splenectomy, a lower complication rate, and a
higher survival associated with this procedure compared to2 Thrombosis
men [4]. These suggestions of survival diﬀerences by gender
have not been conﬁrmed, but a recent publication analyzing
the National Cancer Institute’s Surveillance, Epidemiology,
and End Results (SEER) Program and the North American
Association of Cancer Registries (NAACCR), suggest a slight
3-year relative survival advantage in women compared to
men (81% versus 79%) [5].
In patients with ET or PV, vascular complications repre-
sented the most common cause of morbidity and mortality
[6]; in PMF, vascular complications were similarly morbid,
as the cardiovascular event rate was comparable to that of
ET [7]. In the population at large, traditionally, coronary
heartdisease (CHD),including myocardial infarctions,more
commonly aﬀect men, and women lag in incidence of CHD
by a decade, though gender diﬀerences narrow with age
[8]. Overall, women have lower age-adjusted incidence of
stroke compared to men, but this is modiﬁed by age, and
when comparing younger women (45–54 years), stroke risk
is increased compared to men [8, 9]. Studies suggest that
incidentvenousthromboembolicevents(VTE)areincreased
inmen,asareratesofVTErecurrence[10–12].Todetermine
the inﬂuence of gender on vascular complications in the
MPN, we analyzed associations between gender and vascular
complication rate and type; we hypothesized that male sex
wouldinﬂuencethetendencytowardvascularcomplications.
To test this hypothesis, we retrospectively analyzed a cohort
of270JAK2V617F-positive patientsfromtheJohnsHopkins
Center for the Chronic Myeloproliferative Disorders.
2. Methods
The patient cohort included 270 consecutive JAK2 V617F-
positive MPN patients with ET, PV, or myeloﬁbrosis (MF),
which included post-ET and post-PV myeloﬁbrosis patients,
evaluated at the Johns Hopkins Center for the Chronic
Myeloproliferative Disorders between May 2005 and January
2009. The diagnoses of PV and ET were based on the Poly-
c y t h e m i aV e r aS t u d yG r o u pc r i t e r i a[ 13, 14]; the diagnosis
of PMF was based on Italian Consensus criteria [15, 16].
MF patients with antecedent ET or PV were characterized
accordingly as post-ET MF or post-PV MF [16]. All patients
gave written consent for venipuncture and allowed their
clinical and laboratory data to be recorded in a database for
later analysis; the development of this database was approved
by the Johns Hopkins University Institutional Review Board.
2.1. Outcome and Variable Assessment. This study was ret-
rospective, and data were derived from abstraction of the
medical records, using initial consultation notes and visit
notes corresponding with the date of JAK2 V617F allele
burden analysis. A history of vascular complication was
the outcome of interest; events within 5 years preceding,
or at any time following an oﬃcial diagnosis of ET (n =
61), PV (n = 161), or MF (post-ETMF, post-PVMF, and
PMF) (n = 48) were included. Vascular complications
were characterized as major arterial (cardiac, or neurologic);
major venous (deep vein thrombosis/pulmonary embolism
(DVT/PE), abdominal venous thrombosis (AVT) (splenic
vein, mesenteric vein, portal vein, and hepatic vein throm-
bosis), and sinus venous thrombosis)), and minor events
(transient ischemic attack (TIA); microvascular disturbance
(visual change or digital ischemia), and peripheral arterial
thrombosis)). When available, the interval of time between
MPN diagnosis and the ﬁrst vascular event was recorded,
as well as the age at the ﬁrst vascular event. Traditional
thrombotic risk factors were recorded as binary variables,
including hypertension (by antihypertensive use or medical
history), dyslipidemia (by cholesterol-lowering agent use or
medical history), diabetes mellitus, and smoking history.
The JAK2 V617F allele burden was measured using
an allele-speciﬁc, quantitative real-time polymerase chain
reaction (PCR) assay sensitive to 5% of either the wild-type
or mutant JAK2 allele; intra-assay replicates did not vary
more than 5%, as previously described [1]. A homozygous
genotype was determined based on a JAK2 V617F allele
burden of ≥55%, while those allele burdens <55% were con-
sidered to reﬂect a heterozygous genotype. Disease duration,
antiplatelet use (aspirin) or anticoagulant use (warfarin),
cytoreductive or other therapy (hydroxyurea, anagrelide,
and interferon), spleen size, white blood cell count (WBC),
hemoglobin, and platelet count were assessed at the time of
JAK2 V617F determination.
2.2. Statistical Analysis. Distribution of outcomes and
covariates were described by gender: median and inter-
quartile range (IQR) for skewed continuous variables, and
number (N) and percent (%) for categorical variables. The
Mann-Whitney Rank Sum test was used for hypothesis
testing of gender diﬀerences for continuous variables as
appropriate. Testing for gender diﬀerences in proportions
was performed using the z test, or the chi-square statistic
when appropriate; Fisher’s exact test was used when cell
counts in the contingency table were small. Data were
analyzed using the STATA 10.1 program (STATA Corp.,
College Station, Tex).
3. Results
3.1. Baseline Characteristics. The 270-patient cohort inclu-
ded 164 women and 106 men; women were more likely
to distribute in the ET (43/164: 26%) and PV phenotypes
(104/164: 63%) than MF (17/164: 10%) compared to men
who were more likely to distribute in the PV (57/106: 54%)
and MF phenotypes (31/106: 29%) than ET (18/106: 17%)
(P = 0.001). Women were younger at diagnosis, with a
median age diﬀerence of 6 years (P = 0.001). The median
disease duration for all patients was 5 years. The prevalence
of hypertension and diabetes mellitus was similar between
genders, but women were less likely to have a history of
dyslipidemia (9% versus 25%; P = 0.001) or a history of
tobacco use (22% versus 39%; P = 0.01). The prevalence of
anti-platelet use (aspirin or clopidogrel) and anticoagulation
(warfarin) was similar between men and women. Among
laboratory parameters (assessed at the time of JAK2 V617F
allele burden determination), the median hemoglobin and
platelet counts were similar, but women had lower medianThrombosis 3
white blood cell counts (9.5k/cumm versus 13.2 × 109/L;
P = 0.02). The median JAK2 V617F allele burden was higher
in men compared to women (63% versus 53%; P = 0.05).
There were no diﬀerences in the prevalence of MPN-directed
therapies,includinghydroxyurea(P = 0.28);anagrelide(P =
0.42); interferon(P = 1) between men andwomen (Table 1).
3.2. Vascular Complication History. In the whole cohort, 63
of 270 (23%) patients had a history of vascular complica-
tions; there were no statistical diﬀerences in rate of these
complications between those with ET (13/61: 21%); PV
(40/161: 25%); or MF (10/48: 21%). Of 164 women, 44
(27%) had a history of a vascular complication, compared
to 19 of 106 men (18%); however, this diﬀerence was
not statistically signiﬁcant (P = 0.09). Ten patients had
multiple vascular events, of which 7 were women. Among
the 10 patients with multiple events, in most cases, diﬀerent
vascular beds were involved (Table 2). The median age at the
time of vascular event did not diﬀer by gender (56 years in
men and women).
3.3. Type of Vascular Event. Among men, of 24 events, 10
(42%) were major venous events, 8 were minor events
(33%), and 6 (25%) were major arterial events (25%). The
most commonly aﬀected vascular beds were cardiac (acute
coronary syndromes in 5 men) or the deep venous system
(deep vein thrombosis or pulmonary embolism in 5 men).
Similarly, in women, of 51 events, 25 (49%) experienced
major venous events, 15 (29%) had minor events, and 11
(22%) had major arterial vascular complications. However,
in women, the most commonly aﬀected vascular bed
involvedtheabdominalvenoussystem(AVT);16of51(31%)
events involved the hepatic, portal, mesenteric, or splenic
veins. Among women with AVT, most had PV (10/16: 63%),
often involving the hepatic vein (Budd-Chiari syndrome).
However, in women with MF, AVT involved the portal vein
in3casesandwasanassociatedcomplicationofsplenectomy
in 2 of these cases. Transient ischemic attacks (8 events)
and DVT/PE (8 events) represented the next most common
type of vascular complication, followed by cerebrovascular
accident (6 events). Chemotherapy or aspirin use at the time
of the event did not diﬀer by gender and was present in 9%
and 18% of the cohort, respectively.
3.4. Timing of 1st Vascular Event. The time of the ﬁrst
vascular event was known for 13 of 18 men (Figure 1).
Among these, 12/13 (92%) had an event during the ﬁrst
decade of their disease. Ten (77%) either presented with a
vascular complication (year 0 in Figure 1) that led to the
oﬃcial MPN diagnosis (7 men), or had an event in the
preceding 5 years (3 men). Of the 7 men who presented
with a vascular event leading to MPN diagnosis (year 0 in
Figure 1), 1 (14%) had an abdominal venous thrombosis, 2
had DVT/PE, 2 had microvascular disturbances, and 2 had
ACS.
Among 44 women, the time of event in relation to
diagnosis was known for 41 (Figure 1). Thirty-three of 41
(80%) women experienced a vascular complication during
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Figure 1: Major and minor vascular events through the course of
the disease. The timing of vascular complication was known for
13 men and 41 women. In both men and women, vascular com-
plications often lead to an oﬃcial diagnosis of a myeloproliferative
neoplasm (complication at year 0). Further, vascular complications
predominantly occurred in the ﬁrst decade of disease in both men
and women. Of the 15 women with vascular complications at year
0, 9 had abdominal venous thrombosis.
the ﬁrst decade of disease. Twenty of 41 (49%) women
either presented with a vascular complication that led to an
oﬃcial MPN diagnosis (15 women), or had an event in the
preceding 5 years (5 women); this proportion was lower, but
notstatisticallydiﬀerentwhencomparedtomen(49%versus
77%; P = 0.076), suggesting a trend among women who
weremorelikelytoexperienceacomplicationafteranoﬃcial
diagnosis compared to men. The median time to a vascular
event was comparable between men and women (0 (range
−5 to 12) years versus 1.0 (range −4t o2 0 )y e a r s ;P = 0.06).
Of the 15 women who presented with a vascular event
leading to an immediate MPN diagnosis (year 0 in Figure 1),
9 (60%) had abdominal venous thrombosis; 8 of these 9
women had PV. One woman was taking oral contraceptives
(OCP) at presentation; 3 had no such history, and exposure
was unknown in the remaining 5 women. Importantly,
compared to men who presented with a vascular event,
this predilection towards AVT at diagnosis was statistically
signiﬁcant (60% versus 14%; P = 0.04). Among the rest
of the women with a vascular events at presentation, 2 had
microvascular complications (both had PV), 2 had cardiac
events(1ET,1PV),1hadaTIA(PV),andonehadabrachial
artery thrombosis (ET).
3.5. Multivariable Regression. In the univariate analysis
(Table 1), there were gender diﬀerences in the whole cohort
with regard to disease distribution, age at diagnosis, smoking
history, dyslipidemia, median white blood cell count, and
median JAK2 V617F allele burden. Therefore, these variables
were incorporated in a multivariable logistic regression
analysis (Table 3). When adjusting for these variables,
women had an odds of a vascular event history that was4 Thrombosis
Table 1: Baseline characteristics in the MPN cohort, by gender.
Female Male P value
Diagnosis, number (%)
All MPN 164 106 0.001
ET 43 (26) 18 (17)
PV 104 (64) 57 (54)
MF 17 (10) 31 (29)
Age at diagnosis, median (IQR)
All MPN 50 (37–61) 56 (48–67) 0.001
ET 50 (36–59) 48 (31–60)
PV 48 (34–61) 56 (50–66)
MF 58 (51–63) 61 (51–67)
Disease duration, median (IQR)
All MPN 5 (3–11) 5 (1–9) 0.04
ET 4 (2–10) 3 (1–9)
PV 6 (3–12) 4 (1–8)
MF 6 (3–12) 6 (2–11)
Hypertension, number (%) 2 missing
All MPN 53 (33%) 44 (42%) 0.15
ET 13 4
PV 35 29
MF 5 11
Diabetes Mellitus, number (%) 1 missing
All MPN 7 (4%) 8 (8%) 0.28
ET 0 0
PV 5 6
MF 2 2
Dyslipidemia, number (%)
All MPN 15 (9) 26 (25) 0.001
ET 2 3
PV 12 15
MF 1 8
Smoking history, number (%)
All MPN 35 (22) 40 (39) 0.005
ET 12 4
PV 17 25
MF 6 11
Median white blood cell count, × 109/L (IQR)
All MPN 9.5 (7.3, 14.8) 13.2 (8.3, 21.4) 0.02
ET 8 (6.8, 9) 8.7 (6–10.8)
PV 11.1 (7.5,18.4) 13.9 (9.6, 20)
MF 25 (6.9, 49) 15.9 (7.9, 26.6)
Median hemoglobin, g/dL; (IQR)
All MPN 12.9 (11.6, 14) 13.2 (11.4, 14.4) 0.73
ET 13.7 (12.7, 14.2) 14.7 (13.2–15.1)
PV 12.8 (11.6, 13.8) 13.6 (12.6–14.4)
MF 10.6 (9.9, 12.5) 10 (9, 11.8)
Median Platelet count, × 109/L (IQR)
All MPN 527 (333, 678) 450 (246–673) 0.09
ET 568 (499–782) 476 (412–654)
PV 526 (340–667) 502 (300–700)
MF 214 (133–330) 272 (166, 477)Thrombosis 5
Table 1: Continued.
Female Male P value
JAK2 V617F allele burden, median (IQR)
All MPN 53 (42–69) 63 (46–83) 0.05
ET 34 (22–44) 44 (34–48)
PV 64 (50–71) 71 (55–88)
MF 82 (55–100) 57 (48–77)
JAK2 genotype 0.1
Heterozygous 86 (53%) 45 (42%)
Homozygous 77 (47%) 61 (58%)
Anti-platelet Use, number (%)
All MPN 81 (59) 69 (69) 0.12
ET 26 11
PV 50 41
MF 5 17
Warfarin Use, number (%)
All MPN 17 (10%) 7 (7%) 0.28
ET 4 3
PV 13 4
MF 0 0
Hydroxyurea Use, number (%)
All MPN 48 (30%) 28 (27%) 0.58
ET 11 3
PV 33 17
MF 4 8
Interferon Use, number (%)
All MPN 5 (3%) 3 (3%) 0.99
ET 0 1
PV 4 0
MF 1 2
Anagrelide Use, number (%)
All MPN 11 (7%) 4 (4%) 0.42
ET 4 1
PV 6 1
MF 1 2
∗7 women with missing data
∗4 men with missing data
∗∗27 women with missing data
∗∗6 men with missing data.
1.9 times higher compared to men (OR 1.89; 95% CI: 0.96,
3.73; P = 0.067). Among the above variables, dyslipidemia
was marginally independently associated with a history of
vascular complication (OR: 2.3; 95% CI: 1.0, 5.3; P = 0.045).
For unknown reasons, those with a history of tobacco use
were less likely to have a history of vascular complication
(OR 0.48; 95% CI: 0.22, 1.0; P = 0.049), but this association
has no biologic rationale, and for practical purposes, is
insigniﬁcant.
4. Discussion
In this MPN cohort, women were younger at diagnosis, were
less likely to have a history of tobacco use or dyslipidemia,
and had lower median white blood cell counts and JAK2
V617 allele burdens, compared to men. Therefore, it was
surprising to us that a history of a vascular event was at
least as common in women, compared to men, with 27%
of women experiencing vascular complications, compared
to 18% of men (P = .09). In multivariable regression
analysis, dyslipidemia associated with a history of a vascular
event. In both men and women, the majority of vascular
complications occurred in the 1st decade of the disease,
similar to what has been observed by others in treated and
untreated ET cases as well as PV cases [17–19]. In both
men and women, a vascular complication often led to the
diagnosis of an MPN. However, the type of event diﬀered,
more commonly involving the abdominal venous system
in women ultimately diagnosed with PV. Therefore, when
evaluating gender diﬀerences in phenotype, an important6 Thrombosis
Table 2: Major and minor vascular events, by gender.
Women (n = 164) Men (n = 106) P value
Vascular event history, number (%) 44 (27) 19 (18) 0.09
ET 8 (18) 5 (26)
PV 31 (71) 9 (47) 0.06
MF 5 (11) 5 (26)
Vascular events, number 51 24
Major Venous Events, number (%) 25(49) 10 (42) 0.57
DVT/PE 8(15.7) 5 (20.8) 0.47
ET 1 0
PV 6 4
MF 1 1
Abdominal venous thrombosis 16(31.4) 4 (16.7) 0.26
ET 2 2
PV 10 1
MF 4 1
Sinus venous thrombosis 1(2) 1 (4.2) 0.61
ET 0 1
PV 1 0
MF 0 0
Major Arterial Events, number (%) 11(22) 6 (25) 0.77
Cardiac (ACS) 5(9.8) 5 (20.8) 0.14
ET 3 1
PV 2 3
MF 0 1
Neurologic (CVA) 6(11.8) 1 (4.2) 0.31
ET 1 0
PV 5 1
MF 0 0
Minor events, number (%) 15(29) 8 (33) 0.73
TIA 8(15.7) 3 (12.5) 0.81
ET 1 0
PV 7 1
MF 0 2
Peripheral arterial thrombosis 3(5.8) 2 (8.3) 0.6
ET 1 0
PV 1 1
MF 1 1
Microvascular disturbance 4(7.8) 3 (12.5) 0.42
ET 2 2
PV 2 1
MF 0 0
ﬁnding emerges: women manifest their MPN diagnosis
diﬀerently, presenting with Budd-Chiari syndrome.
Our association between disease presentation, female
gender, JAK2-V617F positivity, and abdominal venous
thrombosis has also been recognized by others. In a series
of 93 patients with extrahepatic portal vein obstruction
(EHPVO) or Budd-Chiari syndrome (BCS), approximately
60% were women (n = 56); this proportion was similar
when looking at these entities separately [20]. Twelve percent
of aﬀected patients were taking oral contraceptives. The
JAK2 V617F mutation was found in 36.5% of patients [20].
Colaizzo et al. observed 99 patients with portal/mesenteric
vein thrombosis and identiﬁed a JAK2 V617F mutation
in 17 patients [21]. Of these 17, 12 (70%) patients were
women;identiﬁedriskfactorswererareasonly1womanwas
taking an oral contraceptive, 1 had hyperhomocysteinemia,
a n d1h a da b d o m i n a ls u r g e r y[ 21]. In a series of 241
splanchnic vein thrombosis patients, Kiladjian et al. found
JAK2 V617F mutations in 94. Among these 94, 58 were
women [22]. The female predominance was particularlyThrombosis 7
Table 3: Multivariable logistic regression.
Vascular event history Odds ratio P value 95% CI: lower limit 95% CI: upper limit
Female sex 1.89 0.07 0.96 3.73
PV compared to ET 1.06 0.89 .44 2.53
MF compared to ET 1.1 0.87 .35 3.42
Age at diagnosis .99 0.61 .97 1.01
Dyslipidemia 2.31 0.05 1.0 5.34
Smoking history .48 0.049 .23 1.0
White Blood Cell count 1.0 0.66 .98 1.03
JAK2 V617F allele burden 1.0 0.77 .98 1.02
in those with BCS, and among 47 with JAK2 V617F
mutations, 76% were women (n = 36) and most had PV.
Prothrombotic factors, including factor V leiden mutations
(19%), antiphospholipid antibodies (16%), and protein
C deﬁciency (15%) were identiﬁed in those JAK2 V617F
positive patients, but prevalence of OCP use was unknown
[22]. More recently, Colaizzo et al. evaluated 180 patients
with splanchnic vein thrombosis, with an aim of evaluating
whether or not gender modulated the role of JAK2 V617F as
asusceptibilityfactorforSVT[23].Inthisseries,amongSVT
patients, JAK2 V617F was found more frequently in women
compared to men (OR 2.2; 95% CI 1.1–4.5). Further, the
investigators found that the JAK2 46/1 haplotype associated
with the occurrence of somatic JAK2 V617F in women, but
not men. The authors speculated that the higher prevalence
of JAK2 V617F in women with SVT might be accounted
for by sex-related factors that contribute to mutation
development, via the 46/1 haplotype [23].
Our study, like any other observational study, can only
identify associations, rather than implying causal relation-
ships. There remains a potential for residual confounding, as
other unknown factors may account for gender diﬀerences
described in this analysis. Further, oral contraceptive use
was not known for many women, but is a risk factor for
thrombosis, particularly of the abdominal venous system.
However, the aforementioned series of splanchnic vein
thrombosis, OCP use was documented only in the minority
ofJAK2V617F-positivepatients.Likewise,ahypercoagulable
workup was not always done, or available in the medical
record; in Kiladjian’s series, nearly 40% of patients had
identiﬁed abnormalities [22]. Lastly, limitations in power
mayimpederecognitionoftruediﬀerencesbetweenmenand
women in our cohort.
Given the above, the mechanism behind the association
between abdominal venous thrombosis and MPN remains
unknown. Traditional factors that increase vascular risk
in the MPN include age over 60 and prior thrombosis,
and newly suggested risk factors include leukocytosis and
increased JAK2 V617F allele burden [19, 24–26]. In our
series, and that of others with abdominal venous thrombosis
[22], leukocytosis was not prevalent, and JAK2 V617F
allele burdens implied heterozygosity; therefore, a unique
mechanism for thrombosis in this vascular bed exists, and is
probably gender associated.
Our analysis indicates that in the MPN, vascular risk
is not easily attributed to either traditional population risk
factors, or to MPN-speciﬁc, disease burden-related factors.
Despite their younger age, less prevalent dyslipidemia or
smokinghistory,lowerwhitebloodcounts,andalowerJAK2
V617F allele burden, women had higher rates of AVT and
had comparable rates of all other vascular complications.
Our analysis contributes to a growing literature emphasizing
gender diﬀerences in the MPN, which already includes
diﬀerences in the JAK2 V617F allele burden and disease class
and further supports the important impact of individual and
host variation on the clinical manifestations of the MPN
[27].
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